EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease

Rong Peng, Lingzhen Lin, Chengqian Ye

Journal of Gastroenterology · 19.06.2026

DOI: 10.1007/s00535-026-02466-6 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Gastroenterology, online erschienen am 19.06.2026. Verfasst von Rong Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
  • Department of Gastroenterology, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350004, China. yechengqian123@163.com.

Zitieren

APA

Peng, R., Lin, L., & Ye, C. (2026). Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02466-6

Vancouver

Peng R, Lin L, Ye C. Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02466-6

BibTeX
@article{Peng2026,
  author = {Peng, Rong and Lin, Lingzhen and Ye, Chengqian},
  title = {Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease},
  journal = {Journal of Gastroenterology},
  year = {2026},
  doi = {10.1007/s00535-026-02466-6}
}
Kostenlos starten →